Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1904 in advanced solid tumors
NCT04877717Phase 1Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of garetatug rezetecan in solid tumor (advanced stage), gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Hengrui Therapeutics. Primary endpoint: Maximum Tolerated Dose up to 1 year. Started Jul 2021; status: active, not recruiting.
02
Drugs
garetatug rezetecan
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04877717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877717.